References

  1. Chen D, Kristensen D. Opportunities and challenges of developing thermostable vaccines. Expert Rev Vaccines. 2009; 8(5): 547-557. PubMed | Google Scholar

  2. Chen D, Kapre S, Goel A, Suresh K, Beri S, Hickling J et al. Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method. Vaccine. 2010; 28(31): 5093-5099. PubMed | Google Scholar

  3. Karp CL, Lans D, Esparza J, Edson EB, Owen KE, Wilson CB, Heaton PM, Levine OS, Rao R. Evaluating the value proposition for improving vaccine thermostability to increase vaccine impact in low and middle-income countries. Vaccine. 2015; 33(30): 3471-3479. PubMed | Google Scholar

  4. Humphreys G. Vaccination: rattling the supply chain. Bull World Health Organ. 2011; 89(5): 324-325. PubMed | Google Scholar

  5. Zaffran M, Vandelaer J, Kristensen D, Melgaard B, Yadav P, Antwi-Agyei KO, Lasher H. The imperative for stronger vaccine supply and logistics systems. Vaccine. 2013; 31(Suppl 2): B73-B80. PubMed | Google Scholar

  6. World Health Organization (WHO). Use of MenAfriVac™ (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns: Guidance for immunization programme decision-makers and managers - WHO/IVB/13.04. 2013.Geneva. WHO. Accessed 12 February 2015.

  7. Lydon P, Zipursky S, Tevi-Benissan C, Djingarey MH, Gbedonou P, Youssouf BO, et al. Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad. Bull World Health Organ. 2014; 92(2): 86-92. PubMed | Google Scholar

  8. Creese A, Parker D. WHO. Cost analysis in primary health care: A training manual for programme managers. 1994. Geneva. Accessed 12 February 2015.

  9. WHO. Immunization, Vaccines and Biologicals. Immunization Planning and Financing. Accessed 12 February 2015.

  10. PATH. Cold Chain Equipment Manager (CCEM). 2012.Seattle. PATH. Accessed 12 February 2015.

  11. WHO. Guidelines for estimating costs of introducing new vaccines into the national immunization system - WHO/V&B/02.11. 2002.Geneva.WHO. Accessed 12 February 2015.

  12. Levin A, Levin C, Kristensen D, Matthias D. An economic evaluation of thermostable vaccines in Cambodia, Ghana and Bangladesh. Vaccine. 2007; 25(39-40): 6945-6957. PubMed | Google Scholar

  13. Lee BY, Cakouros BE, Assi TM, Connor DL, Welling J, Kone S, et al. The impact of making vaccines thermostable in Niger’s vaccine supply chain. Vaccine. 2012; 30(38): 5637-5643. PubMed | Google Scholar

  14. Otto BF, Suarnawa IM, Stewart T, Nelson C, Ruff TA, Widjaya A, Maynard JE. At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. Vaccine. 1999; 18(5-6): 498-502. PubMed | Google Scholar

  15. Davillou C. Cold chain costing: A study of the costs associated with the yellow fever vaccination campaign in Ghana. World Health Organization Working Paper. April 2012. Unpublished.